Status:
COMPLETED
The Use of Cannabidiol in Cancer Patients
Lead Sponsor:
CHU de Reims
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Alternative and complementary medicines (MAC) are commonly used by cancer patients to help them to face with anticancer treatment, reduce oncology symptoms and/or anticancer treatment adverse effects,...
Detailed Description
* A Prospective observational study * Conducted in an oncology day-hospital (CHU de Reims) All data collected were: * Clinical characteristics, * Administrative data, * Medication review, * Biologic...
Eligibility Criteria
Inclusion
- inclusion criteria: All the patients (\>18yo) who received anticancer treatment
- exclusion criteria:
- Patients who received anticancer drug with very short administration time (typically subcutaneous anticancer drugs as 5-azacitidine, bortezomib and some monoclonal antibodies)
- Patients who were not able to speak and understand French as well as who were unable to communicate clearly.
Exclusion
Key Trial Info
Start Date :
November 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2022
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT05407298
Start Date
November 15 2021
End Date
April 30 2022
Last Update
June 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Damien JOLLY
Reims, France